Movement Alert｜Akeso Bio Falls 3.24% in Regular Trading, Biotech Sector Broadly Retreats After Recent Rally

Market Focus07-07

On July 7, Akeso Bio (09926.HK) fell 3.24% in regular trading, trading at HKD 98.5/share, with turnover of HKD 637 million. The decline came as the broader biotechnology sector experienced a pullback following a multi-day rally driven by innovative drug payment reform catalysts.

The biotech sector saw widespread weakness, with Remegen down 4.95%, Innovent Bio down 2.43%, BeiGene down 2.20%, Keymed Bio-B down 1.73%, and SKB Bio down 1.43%. The sector-wide retreat followed strong gains in prior sessions — Akeso Bio had risen 3.32% on July 6 and surged 8.02% on July 3 — fueled by the National Healthcare Security Administration's announcement of 557 drugs passing initial review for the medical insurance catalog and 54 drugs passing commercial insurance innovative drug catalog review.

Akeso Bio's fundamentals remain supported by multiple institutional buy ratings, with its core product ivonescimab achieving landmark OS data in the HARMONi-6 study and all five self-developed drugs included in the national medical insurance catalog. The company also approved a share repurchase of up to HKD 200 million in June.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1114694866?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-07 13:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114694866","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Akeso Bio Falls 3.24% in Regular Trading, Biotech Sector Broadly Retreats After Recent Rally","media":"Market Focus","content":"<p><p>On July 7, Akeso Bio (09926.HK) fell 3.24% in regular trading, trading at HKD 98.5/share, with turnover of HKD 637 million. The decline came as the broader biotechnology sector experienced a pullback following a multi-day rally driven by innovative drug payment reform catalysts.</p><p>The biotech sector saw widespread weakness, with Remegen down 4.95%, Innovent Bio down 2.43%, BeiGene down 2.20%, Keymed Bio-B down 1.73%, and SKB Bio down 1.43%. The sector-wide retreat followed strong gains in prior sessions — Akeso Bio had risen 3.32% on July 6 and surged 8.02% on July 3 — fueled by the National Healthcare Security Administration's announcement of 557 drugs passing initial review for the medical insurance catalog and 54 drugs passing commercial insurance innovative drug catalog review.</p><p>Akeso Bio's fundamentals remain supported by multiple institutional buy ratings, with its core product ivonescimab achieving landmark OS data in the HARMONi-6 study and all five self-developed drugs included in the national medical insurance catalog. The company also approved a share repurchase of up to HKD 200 million in June.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Akeso Bio Falls 3.24% in Regular Trading, Biotech Sector Broadly Retreats After Recent Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Akeso Bio Falls 3.24% in Regular Trading, Biotech Sector Broadly Retreats After Recent Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-07 13:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 7, Akeso Bio (09926.HK) fell 3.24% in regular trading, trading at HKD 98.5/share, with turnover of HKD 637 million. The decline came as the broader biotechnology sector experienced a pullback following a multi-day rally driven by innovative drug payment reform catalysts.</p><p>The biotech sector saw widespread weakness, with Remegen down 4.95%, Innovent Bio down 2.43%, BeiGene down 2.20%, Keymed Bio-B down 1.73%, and SKB Bio down 1.43%. The sector-wide retreat followed strong gains in prior sessions — Akeso Bio had risen 3.32% on July 6 and surged 8.02% on July 3 — fueled by the National Healthcare Security Administration's announcement of 557 drugs passing initial review for the medical insurance catalog and 54 drugs passing commercial insurance innovative drug catalog review.</p><p>Akeso Bio's fundamentals remain supported by multiple institutional buy ratings, with its core product ivonescimab achieving landmark OS data in the HARMONi-6 study and all five self-developed drugs included in the national medical insurance catalog. The company also approved a share repurchase of up to HKD 200 million in June.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1114694866","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114694866","pubTimestamp":1783400969,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 7, Akeso Bio (09926.HK) fell 3.24% in regular trading, trading at HKD 98.5/share, with turnover of HKD 637 million. The decline came as the broader biotechnology sector experienced a pullback...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"动向提示|康方生物常规交易跌3.24%生物科技板块近期反弹后普遍回调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On July 7, Akeso Bio (09926.HK) fell 3.24% in regular trading, trading at HKD 98.5/share, with turnover of HKD 637 million. The decline came as the broader biotechnology sector experienced a pullback following a multi-day rally driven by innovative drug payment reform catalysts.The biotech sector saw widespread weakness, with Remegen down 4.95%, Innovent Bio down 2.43%, BeiGene down 2.20%, Keymed Bio-B down 1.73%, and SKB Bio down 1.43%. The sector-wide retreat followed strong gains in prior sessions — Akeso Bio had risen 3.32% on July 6 and surged 8.02% on July 3 — fueled by the National Healthcare Security Administration's announcement of 557 drugs passing initial review for the medical insurance catalog and 54 drugs passing commercial insurance innovative drug catalog review.Akeso Bio's fundamentals remain supported by multiple institutional buy ratings, with its core product ivonescimab achieving landmark OS data in the HARMONi-6 study and all five self-developed drugs included in the national medical insurance catalog. The company also approved a share repurchase of up to HKD 200 million in June.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1114694866","isCrawlerRequest":true}